Amneal Pharmaceuticals Inc [AMRX] stock is trading at $7.13, down -3.13%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AMRX shares have gain 2.15% over the last week, with a monthly amount drifted -20.87%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amneal Pharmaceuticals Inc [NASDAQ: AMRX] stock has seen the most recent analyst activity on February 24, 2025, when JP Morgan upgraded its rating to a Overweight and also boosted its price target to $12 from $9. Previously, JP Morgan upgraded its rating to Neutral on September 06, 2024, and kept the price target unchanged to $9. Goldman upgraded its rating to a Buy and increased its price target to $6.50 on March 08, 2021. Guggenheim upgraded its rating to a Buy but $5.50 remained the price target by the analyst firm on December 14, 2020. Barclays upgraded its rating to Overweight for this stock on December 14, 2020, and upped its price target to $6. In a note dated July 27, 2020, Goldman initiated an Sell rating and provided a target price of $4 on this stock.
Amneal Pharmaceuticals Inc [AMRX] stock has fluctuated between $5.18 and $9.48 over the past year. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Amneal Pharmaceuticals Inc [NASDAQ: AMRX] shares were valued at $7.13 at the most recent close of the market. An investor can expect a potential return of 54.28% based on the average AMRX price forecast.
Analyzing the AMRX fundamentals
Amneal Pharmaceuticals Inc [NASDAQ:AMRX] reported sales of 2.79B for the trailing twelve months, which represents a growth of 18.40%. Gross Profit Margin for this corporation currently stands at 0.37% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at -0.02%, and Net Profit Margin reading is -0.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is 1.44 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-3.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.00 points at the first support level, and at 6.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.27, and for the 2nd resistance point, it is at 7.42.
Ratios To Look Out For
For context, Amneal Pharmaceuticals Inc’s Current Ratio is 1.41. In addition, the Quick Ratio stands at 0.86 and the Cash Ratio stands at 0.1. Considering the valuation of this stock, the price to sales ratio is 0.80.
Transactions by insiders
Recent insider trading involved Patel Gautam, Director, that happened on Apr 01 ’25 when 80000.0 shares were sold. 10% Owner, Patel Tushar Bhikhubhai completed a deal on Mar 14 ’25 to sell 5.0 million shares. Meanwhile, 10% Owner Patel Tushar Bhikhubhai bought 5.0 million shares on Mar 14 ’25.
